Detalles de la búsqueda
1.
Second-line chemoimmunotherapy with nivolumab and paclitaxel in immune-related biomarker-enriched advanced gastric cancer: a multicenter phase Ib/II study.
Gastric Cancer
; 27(1): 118-130, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37906316
2.
Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Invest New Drugs
; 39(5): 1366-1374, 2021 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33723724
3.
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR-Mutated NSCLC?
Lung Cancer (Auckl)
; 15: 81-85, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38818015
4.
Path Less Traveled: Targeting Rare Driver Oncogenes in Non-Small-Cell Lung Cancer.
JCO Oncol Pract
; 20(1): 47-56, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37733983
5.
Successful Rechallenge of Trastuzumab Deruxtecan After Drug-Induced Interstitial Lung Disease in a NSCLC With HER2 Mutation: A Case Report.
JTO Clin Res Rep
; 5(2): 100628, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38298273
6.
Analysis of tumor mutational burden and mutational landscape comparing whole-exome sequencing and comprehensive genomic profiling in patients with resectable early-stage non-small-cell lung cancer.
Ther Adv Med Oncol
; 16: 17588359241240657, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38523846
7.
First-in-Human Phase 1 Study of a B Cell- and Monocyte-Based Immunotherapeutic Vaccine against HER2-Positive Advanced Gastric Cancer.
Cancer Res Treat
; 56(1): 208-218, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37402409
8.
Discovery of a Novel Potent EGFR Inhibitor Against EGFR Activating Mutations and On-Target Resistance in NSCLC.
Clin Cancer Res
; 30(8): 1582-1594, 2024 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38330145
9.
CD81 and CD82 expressing tumor-infiltrating lymphocytes in the NSCLC tumor microenvironment play a crucial role in T-cell activation and cytokine production.
Front Immunol
; 15: 1336246, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38515751
10.
Exploring aryl hydrocarbon receptor expression and distribution in the tumor microenvironment, with a focus on immune cells, in various solid cancer types.
Front Immunol
; 15: 1330228, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38680496
11.
ASO Author Reflections: Prognostic Impact of Body Composition Change After Gastrectomy for Advanced Gastric Cancer.
Ann Surg Oncol
; 25(Suppl 3): 765-766, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30421047
12.
Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations.
Ther Adv Med Oncol
; 15: 17588359221146131, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36756143
13.
Clinical utility of a plasma-based comprehensive genomic profiling test in patients with non-small cell lung cancer in Korea.
Cancer Treat Res Commun
; 36: 100715, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37307681
14.
Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study.
Lung Cancer
; 180: 107213, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37104879
15.
Polo-like Kinase 4: A Multifaceted Marker Linking Tumor Aggressiveness and Unfavorable Prognosis, and Insights into Therapeutic Strategies.
Cancers (Basel)
; 15(18)2023 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-37760631
16.
Immune Checkpoint Inhibitors in 10 Years: Contribution of Basic Research and Clinical Application in Cancer Immunotherapy.
Immune Netw
; 22(1): e2, 2022 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35291660
17.
Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC.
Cancer Discov
; 12(1): 16-19, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35022206
18.
Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy.
Ther Adv Med Oncol
; 14: 17588359221141761, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36544541
19.
Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).
Korean J Intern Med
; 37(1): 190-200, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34929077
20.
Incorporation of SKI-G-801, a Novel AXL Inhibitor, With Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor Activity and Survival by Enhancing T Cell Immunity.
Front Oncol
; 12: 821391, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35356198